Clinical trials: Leucovorin
Metastatic Colorectal Carcinoma
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI.
- Trial name
- NCT01937715
- Testing
- PF-05212384, FOLFIRI regimen, Bevacizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 18 people
- Sponsor
- Pfizer
Ovary Cancer
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors.
- Trial name
- NCT03011320
- Testing
- EC1456, 99mTc-Etarfolatide
- Where
- 2 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Endocyte
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Neoplasms, Colonic Neoplasms
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00056459
- Testing
- Vatalanib
- Where
- 223 sites in United States, Australia and 17 more
- Volunteers
- 1,168 people
- Sponsor
- Novartis
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab…
- Trial name
- NCT05609370
- Testing
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar
- Where
- 64 sites in United States, Australia and 2 more
- Volunteers
- 113 people
- Sponsor
- BeiGene
Metastatic Colorectal Cancer, KRAS Gene Mutation
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line…
- Trial name
- NCT03829410
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Cardiff Oncology
Colorectal Cancer
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01133990
- Testing
- FOLFIRI, E7820, Bevacizumab
- Where
- 34 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Eisai Inc.
Metastatic Colorectal Cancer
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
The purpose of this study is to determine the treatment effect of QL1203 in combination with mFOLFOX6 compared to Placebo in combination with mFOLFOX6 as first line therapy for metastatic colorectal cancer.
- Trial name
- NCT04233151
- Testing
- QL1203, mFOLFOX6 regimen
- Where
- 2 sites in China
- Volunteers
- 590 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
A Clinical Study of Arfolitixorin in Patients With mCRC
This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.
- Trial name
- NCT06922383
- Testing
- Arfolitixorin, Leucovorin
- Where
- 3 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Isofol Medical AB
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic…
- Trial name
- MTAPESTRY 103 (NCT06360354)
- Testing
- Anvumetostat, Gemcitabine, Nab-paclitaxel
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 120 people
- Sponsor
- Amgen
Metastatic Pancreatic Cancer
A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)
The aim of this phase 4 study is to evaluate the safety profile of ONIVYDE in China mainland. Primary objective To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following…
- Trial name
- SEOPAC (NCT06688240)
- Volunteers
- 120 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Metastatic Colorectal Cancer
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 ± cetuximab.
- Trial name
- NCT03426371
- Testing
- KL-140
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no previous treatment for advanced…
- Trial name
- NCT01506167
- Testing
- Bevacizumab, Capecitabine/Oxaliplatin, Fluorouracil/Folinic Acid/Oxaliplatin
- Where
- 43 sites in United Kingdom
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreas Adenocarcinoma
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic…
- Trial name
- FABLOx (NCT02620800)
- Testing
- 5FU, nab-paclitaxel, bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Pancreatic Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with…
- Trial name
- NCT03193190
- Testing
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin
- Where
- 23 sites in United States, Germany and 3 more
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin…
- Trial name
- NCT00061815
- Testing
- cetuximab, oxaliplatin, leucovorin
- Where
- 39 sites in United States
- Volunteers
- 102 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Adenocarcinoma
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Trial name
- NCT06396091
- Testing
- zolbetuximab, mFOLFIRINOX
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Global Development, Inc.
First-line Treatment of Advanced Pancreatic Cancer
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall…
- Trial name
- NCT05751850
- Testing
- HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 778 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens.
- Trial name
- NCT06509906
- Testing
- M9466, Irinotecan, Folinic acid
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX).
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04430738
- Testing
- tucatinib, trastuzumab, oxaliplatin
- Where
- 27 sites in United States, Japan
- Volunteers
- 40 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer